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Background: Skeletal muscle function depends on calcium signaling proteins in the sarcoplasmic reticulum (SR),
including the calcium-binding protein calsequestrin (CSQ), the ryanodine receptor (RyR) calcium release channel,
and skeletal triadin 95 kDa (trisk95) and junctin, proteins that bind to calsequestrin type 1 (CSQ1) and ryanodine
receptor type 1 (RyR1). CSQ1 inhibits RyR1 and communicates store calcium load to RyR1 channels via trisk95
and/or junctin.
Methods: In this manuscript, we test predictions that CSQ1’s acidic C-terminus contains binding sites for trisk95
and junctin, the major calcium binding domain, and that it determines CSQ1’s ability to regulate RyR1 activity.
Results: Progressive alanine substitution of C-terminal acidic residues of CSQ1 caused a parallel reduction in the
calcium binding capacity but did not significantly alter CSQ1’s association with trisk95/junctin or influence its
inhibition of RyR1 activity. Deletion of the final seven residues in the C-terminus significantly hampered calcium
binding, significantly reduced CSQ’s association with trisk95/junctin and decreased its inhibition of RyR1. Deletion
of the full C-terminus further reduced calcium binding to CSQ1 altered its association with trisk95 and junctin
and abolished its inhibition of RyR1.
Conclusions: The correlation between the number of residues mutated/deleted and binding of calcium, trisk95,
and junctin suggests that binding of each depends on diffuse ionic interactions with several C-terminal residues
and that these interactions may be required for CSQ1 to maintain normal muscle function.
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In skeletal muscle, the rapid and co-ordinated release of
calcium ions from the internal sarcoplasmic reticulum
(SR) store is essential in triggering muscle contraction.
Skeletal muscle activation, in response to an action
potential on the surface membrane, activates voltage-
gated L-type Ca2+ channels which, in turn, initiate SR
Ca2+ release. The SR Ca2+ release channel is the ligand-
gated ryanodine receptor (RyR), a large (>2 mDa) homo-
tetrameric ion channel, which releases between 10% to
17% of the total SR Ca2+ with each action potential* Correspondence: nicole.beard@canberra.edu.au
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article, unless otherwise stated.(reviewed in [1]). Ryanodine receptor type 1 (RyR1) is
central to excitation-contraction coupling, and its activ-
ity and ability to release Ca2+ is refined by the level of
Ca2+ load inside the SR and by a luminal SR protein
complex, including calsequestrin (CSQ), skeletal triadin
95 kDa (trisk95), and junctin.
CSQ is the most abundant Ca2+ buffering protein found
within the SR, with its concentration reported to be be-
tween 11 and 36 μmol (l fiber volume)−1, dependent on
muscle type [2]. Calsequestrin type 1 (CSQ1) is the only
isoform expressed in fast twitch muscle fibers, while equal
amounts of CSQ1 and the so-called cardiac CSQ2 isoform
are expressed in slow twitch fibers [2]. Both isoforms
display a high degree of homology, with the C-terminal
tail extended in CSQ2. CSQ1 is a low affinity, moderate
to high-capacity Ca2+-binding protein, binding betweenCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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mately 1 to 2 mM [3,4]. CSQ1 buffers free SR Ca2+ to
approximately 1 mM during the contraction/relaxation
cycle.
Research over the past 2 decades has shown that CSQ1
plays additional roles in global regulation of Ca2+ signal-
ing in skeletal and cardiac muscles. A retrograde signal
from CSQ1 is thought to be important for store-operated
Ca2+ entry in skeletal muscle [5]. CSQ1 inhibits RyR1,
while in the heart, CSQ2 activates the cardiac RyR [6].
CSQ is considered to be a luminal Ca2+ sensor for the
RyR, communicating Ca2+ store load to the channel
[7-9]. In skeletal muscle, CSQ1 acts as a break on the
channel, to curtail SR Ca2+ release under conditions of
lower store load and is essential for normal muscle func-
tion. Knockout of CSQ1 leads to a malignant hyperthermia
phenotype with excess Ca2+ release under stress [10]. Des-
pite the functional interaction between CSQ1 and
RyR1, there is no evidence that they bind directly
in vivo. Instead, both proteins bind to junctin and
trisk95 [11-16], forming a luminal protein complex,
which allows CSQ1-RyR1 communication. The im-
portance of the luminal protein complex in mo-
dulating RyR activity and excitation-contraction
coupling is highlighted by the fact that mutation or
alteration in expression of these proteins results in
severe contractile dysfunction [17-23].
At in vivo luminal [Ca2+]s, CSQ1 monomers self-
associate to form polymers, which are observed as long
linear strand-like structures closely associated with the
junctional face membrane in electron micrographs [24].
The dynamic polymerization of CSQ1 is highly
dependent on Ca2+. At low [Ca2+] of 100 nM, CSQ1 ex-
ists in an unfolded randomly coiled structure [25]. As
[Ca2+] is increased toward 100 μM, CSQ1 undergoes a
conformational change [25-27] and increases in helicity
[26,28]. The conformational changes include the folding
of the three thioredoxin domains within CSQ1 and the
subsequent formation of front-to-front dimers between
two folded monomers [27]. In this process, the N-
terminus from one monomer inserts into a groove be-
tween two β-strands of domain II of the second mono-
mer [27]. A secondary intermolecular interaction among
front-to-front dimers allows them to associate in a back-
to-back configuration, bringing together two electro-
negative surfaces to form linear polymers [27].
Several factors influence CSQ1’s moderate to high Ca2+
binding capacity. Ca2+ binding capacity is partially deter-
mined by overall net charge [29]; however, the calculated
net charge of skeletal CSQ1 is insufficient for the amount
of Ca2+ that it can bind in its polymer form [30]. This
suggests that additional sites for Ca2+ binding must be
formed as CSQ1 polymerizes. The roles of the acidic-rich
C-terminal tail (residues 354 to 367 in rabbit) has beenpostulated to play an important role in inferring the Ca2+
binding capacity of CSQ1 [15,29,31], although the mech-
anisms have not been well understood. Recent molecular
dynamic modeling studies postulate that Ca2+ binding
sites within the C-terminus of CSQ1 serve to neutralize
the interface and enable CSQ polymerization and subse-
quent high-capacity Ca2+ binding [32]. Furthermore, the
existence of low-affinity Ca2+ binding sites on CSQ1 may
serve, at least in part, to induce additional Ca2+ binding
sites [32], allowing for CSQ’s high-capacity Ca2+ binding.
That the C-terminal tail is essential for binding capacity
is supported experimentally, as its deletion in CSQ2
severely reduces Ca2+ binding capacity [29]. The C-
terminal tail contains the highest surface negative charge
density [30] and was initially thought to be responsible
for at least 26% of the Ca2+ binding, although simulations
suggest this to be as low as 10% [32].
CSQ1’s acidic-rich C-terminal tail also constitutes a
“hot spot” for CSQ1 protein associations. CSQ1 resi-
dues 354 to 367 contain the binding site for trisk95
and have been suggested to contain critical residues
that support its interaction with junctin [15]. We are
yet to understand the true nature of this region, be-
cause the anatomical details of the acidic C-terminal
tail are not resolved in published crystal structures of
CSQ1 (reviewed in [33]) and because there is little infor-
mation on the role of specific residues within the C-
terminal tail in the various functions of CSQ1.
In this paper, we have dissected the functional import-
ance of residues within CSQ1’s C-terminal tail. We have
examined the effects of substitutions or deletions within
the C-terminal tail on CSQ1’s Ca2+ binding capacity, its
ability to associate with trisk95 and junctin and its ability
to regulate RyR1 channel activity to ensure normal
muscle function.
Methods
Materials
The monoclonal 34C anti-RyR1 antibody, monoclonal
VIIID12 anti-CSQ1 antibody, and rabbit affinity-
isolated polyclonal anti-CSQ antibody (ab 3516) were
from Abcam (Cambridge, MA, USA). Polyclonal anti-
junctin was a generous gift from Dr. Steven Cala
(Wayne State University, MI, USA). Phospholipids
were from Avanti Polar Lipids (Alabaster, AL, USA).
The Pierce IP kit was from ThermoFisher Scientific
(Scoresby, Vic, Australia), 45Ca2+ was from PerkinEl-
mer (Glen Waverley, VIC, Australia), and Glutathione
Sepharose 4B was from GE Healthcare (Rydalmere,
NSW, Australia). The Bio-Rad DC protein determin-
ation assay and sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE)/Western blot apparatus
and consumables were from Bio-Rad (Gladesville, NSW,
Australia), and the multi-mutagenesis kit was from
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VIC, Australia). Microcon centrifugal filter concentra-
tors were from Millipore (Bayswater, VIC, Australia).
The monoclonal anti-triadin antibody (IIG12) and all
other chemicals were obtained from Sigma-Aldrich
(Castle Hill, NSW, Australia).Ethics approval
All animal work was approved by the Australian National
University and University of Canberra Animal Ethics
Committees.CSQ1 mutation, expression, and purification
To probe the functional importance of the acidic-rich
C-terminal tail in CSQ1, wild-type (WT) CSQ1 and
several alanine substitution and deletion mutants (see
Figure 1) were generated by PCR of rabbit CSQ1 cDNA
using the Stratagene multi-mutagenesis kit. All CSQ1
constructs were subcloned into a pGEX5x1 vector, con-
taining a N-terminal glutathione S-transferase (GST)
tag and expressed as previously described [34]. The
expressed CSQ1 proteins were dialyzed against 20 mM
MOPS, 150 mM NaCl, and 1 mM CaCl2 (pH 7.4).
Where necessary, the protein underwent secondary
purification using anti-CSQ1 immunoprecipitation
(Pierce crosslinking IP kit), following manufacturer’s
instruction.Figure 1 CSQ1 mutation and expression. (A) Diagram of the
CSQ1 alanine point mutations and deletion mutants. (B) SDS-PAGE
and silver stain of purified CSQ1 WT and mutant constructs. From
left to right, WT CSQ1, CSQ1DA1, CSQ1DA2, CSQ1DA3, CSQ1ΔC7, and
CSQ1ΔC14. Molecular weight markers are to the left of the blot in (B).SR vesicle preparation
SR vesicles from back and leg muscles from New Zealand
White Rabbits were prepared as described in [7,9,35].
RyR1 purification from skeletal SR vesicles was per-
formed as described in [36]. The purified RyR1 was con-
centrated, snap-frozen, and stored at −70°C. The protein
was run on SDS polyacrylamide gels, and immunoblots
probed with anti-RyR1, anti-CSQ1, anti-triadin and anti-
junctin antibodies to detect contamination by these
proteins.
SDS-PAGE and Western blot were performed accord-
ing to [37,38]. Briefly, proteins were separated on 4% to
15% or 4% to 20% SDS polyacrylamide gels and trans-
ferred to polyvinylidene difluoride (PVDF) membrane
for Western blot. PVDF membranes were exposed to
primary antibodies to CSQ1, junctin, trisk95, and RyR1
(as appropriate) and secondary HRP-conjugated anti-
body, prior to chemiluminsence detection. Images were
developed using a Kodak OXmat M20 film processor
onto Kodak Hyper ECL film.
Purification of trisk95 and junctin from skeletal SR
vesicles
Trisk95 and junctin were isolated by SDS preparative gel
electrophoresis, as previously described [39].
Ca2+ binding capacity
The Ca2+ binding capacities of CSQ1 constructs were
determined using a modified 45Ca2+ spin dialysis bind-
ing assay [14]. In brief, 200 μg of CSQ1 constructs were
conjugated with 45Ca2+ by incubation in 150 mM NaCl,
20 mM MOPS, 100 μM to 5 mM CaCl2 (pH 7.4), and
2.6 kBq 45Ca2+ for 15 min at room temperature. Un-
conjugated 45Ca2+ was removed by centrifugation of
the samples in a Microcon centrifugal filter concentra-
tor at 12,000 × g for 10 min. 45Ca2+ radioactivity of the
retentate (containing CSQ1-45Ca2+) and of an unfiltered
sample aliquot were counted using a Packard 1500 Tri-
Carb liquid scintillation analyzer (Packard Instrument
Co., Downers Grove, IL, USA). Protein concentration
of the retentate (containing CSQ1-45Ca2+) was deter-
mined using a Bio-Rad DC protein determination assay,
according to manufacturer’s instruction. Data is pre-
sented as nmol 45Ca2+/mg CSQ1.
Co-immunoprecipitation
In vitro binding of CSQ1 to purified trisk95 and junctin
was performed using a Pierce co-immunoprecipitation
kit as per manufacturer’s instruction, with the following
changes. Co-immunoprecipitation was performed in a
buffer containing 20 mM MOPS, 150 mM NaCl, and 1
mM CaCl2 (pH 7.4), using a 2:1 protein ratio (weight) of
CSQ1 to either junctin, trisk95, or RyR1.
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CSQ1-RyR1 interactions were investigated using affinity
chromatography as previously described [34].
Turbidity measurements
Solution turbidity [40,41] was monitored spectrophoto-
metrically in a 1-cm path length quartz cuvette. Three
micromolar protein was suspended in a buffer contain-
ing 20 mM Tris and 100 mM KCl pH 7.4. Small aliquots
of CaCl2 were added to the cuvette to final concentra-
tions of 0.1 to 3 mM. After each addition, the cuvette
was stirred and allowed to equilibrate at room
temperature for 7.5 min, after which the absorbance
was recorded at 350 nm. Absorbance values were cor-
rected for any change in absorbance due to buffer
alone. Turbidity is a measure of CSQ1 transition from
soluble to insoluble forms as a function of [Ca2+], and
increased absorbance at 350 nm reflects the shift
toward insoluble particles.
Single channels
Artificial planar bilayers separating two baths (cis and
trans) were formed as described previously [7,34].
Native SR vesicles (50 μg) or purified RyR1 (10 μg)
were added to the cis solution so that the cytoplasmic
surface of the SR and RyR1 faced this solution after in-
corporation. Solution constituents were as follows: cis -
230 mM CsMS, 20 mM CsCl, 1 mM CaCl2, and 10 mM
TES (pH 7.4) and trans - 30 mM CsMS, 20 mM CsCl,
1 mM CaCl2, and 10 mM TES (pH 7.4). Free [Ca
2+] in
all solutions was verified using a Ca2+ electrode. Single
channel parameters were measured using the channel
2 program (developed by P.W. Gage and M. Smith,
John Curtin School of Medical Research, Canberra,
Australia). Single channel recordings were obtained at
+40 and −40 mV, at 23 ± 2°C. Channel activity was
assessed from 90 s of recording at each potential, by
directly measuring open probability (Po), mean open
time (To), mean closed time (Tc), and open frequency
(Fo) in single channel recordings using threshold dis-
crimination or indirectly from the fractional mean
current (I’F) when more than one channel was opening
[9]. For simplicity, Po and I’F are combined in calcula-
tions of average Po or relative Po [9].
Statistics
Average data are presented as mean ± SE. The significance
of differences between control and test values was tested
using a Student’s t-test for paired data. In some cases, to
reduce the effects of variability in control parameters
(PoCon, ToCon, TcCon, and FoCon) and to evaluate parameters
after CSQ1 construct addition (PoCSQ, ToCSQ, TcCSQ, and
FoCSQ), data were expressed as the difference between
log10XCSQ and log10XCon for each channel (for example,logPoCSQ − logPoCon). The difference from control was
assessed with a paired t-test applied to log10XCon and
log10XCSQ. A P value of ≤0.05 was considered to be
significant.Results
Expression of CSQ1
CSQ1 contains a highly acidic-rich C-terminal domain,
354EDDDDEDDDDDDDD367, purported to be a Ca2+
binding motif, and contains residues essential for bind-
ing both junctin and trisk95 [15]. To investigate the
function of the CSQ1 C-terminal domain, we generated
two deletion mutants of GST-tagged rabbit CSQ1 and
three alanine substitution mutants. The two CSQ1 dele-
tion mutants were generated by deleting either the
whole C-terminal tail (CSQ1ΔC14) or 50% of the tail
(CSQ1ΔC7) (Figure 1A). As CSQ Ca
2+ binding motifs
consist of a pair of acidic residues located close in space
(with each pair binding one calcium ion), alternate acidic
residues were substituted to disrupt one (CSQ1DA1), two
(CSQ1DA2), or three (CSQ1DA3) Ca
2+ binding sites
within the sequence (Figure 1A). For single channel and
45Ca2+ binding studies, CSQ1 constructs were cleaved
from the GST by incubation with the serine endopeptid-
ase Factor Xa and purified to homogeneity (Figure 1B).Effects of C-terminal tail modification on the Ca2+ binding
capacity of CSQ
The Ca2+ binding capacity of the CSQ1 constructs was
determined using 45Ca2+ binding. Ca2+ binding capacity
is dependent on CSQ1 structure and increases sharply
as CSQ1 polymerizes. Given that CSQ1’s C-terminus is
believed to form a large acidic Ca2+ binding pocket upon
polymerization [27], it follows that disruption of this
pocket would reduce Ca2+ binding capacity. Mutation of
one or two acidic residues (CSQ1DA1 and CSQ1DA2)
within the C-terminus had no significant effect on Ca2+
binding capacity from 0.1 to 1 mM Ca2+, and the bind-
ing curves were similar to that we have previously re-
ported [42], but CSQ1DA2 bound significantly less Ca
2+
than WT CSQ1 at 2 mM Ca2+ (Figure 2). Mutation of
three acidic residues (CSQ1DA3) was sufficient to reduce
Ca2+ binding capacity to approximately 70% of WT
CSQ1 at resting [Ca2+] of 1 mM and to significantly
depress binding capacity at all other [Ca2+] tested. Trun-
cation of the C-terminus (CSQ1ΔC7) led to a 40% to 60%
drop in Ca2+ binding capacity at all [Ca2+] tested, while
removing the entire C-terminus (CSQ1ΔC14) all but
abolished Ca2+ binding (Figure 2). This provides further
strong evidence that many of the C-terminal acidic resi-
dues of CSQ1 are key to the formation of a Ca2+ binding
pocket, which enhances CSQ’s Ca2+ binding capacity.
Figure 2 CSQ1 Ca2+ binding capacity. The 45Ca2+ binding in a
spin dialysis binding assay was carried out using 200 μg protein (at a
concentration of 1 mg/ml) in 150 mM NaCl, 20 mM MOPS, 100 μM
to 5 mM CaCl2, and 2.6 kBq
45Ca2+. Each data point is the mean
45Ca2+ bound, in nmol Ca2+/mg CSQ, and the bars are SEM for each
of the CSQ1 constructs, under the Ca2+ conditions listed. Asterisks (*)
indicate a significant difference in 45Ca2+ bound to CSQ1 constructs
compared to WT CSQ1 (P < 0.05). N = 5 to 9.
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Figure 3 CSQ C-terminal tail contributes to CSQ1 aggregation.
CSQ turbidity, an indicator of polymerization and aggregation, is
measured as absorbance at 350 nm. Experiments were carried out in
a buffer containing 20 mM MOPS, 100 mM KCl, and 0 to 3 mM
CaCl2. Data is presented as mean ± SEM for each of the CSQ1
constructs. Asterisks (*) indicate average data significantly different
(P ≤ 0.05) from that of WT CSQ1 at the same [Ca2+].
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To determine whether mutation of the acidic C-terminus
disrupted CSQ1 aggregation, turbidity measurements were
performed. CSQ1 and CSQ2 undergo Ca2+-induced com-
paction or a shift from the proteins soluble to insoluble
form [41]. CSQ1 aggregation is measured as turbidity
(absorbance at 350 nm), which is proportional to the levels
of insoluble CSQ1 [40,41]. The turbidity of WT CSQ1
increases sigmoidily across the [Ca2+] range tested, reaching
a constant concentration of insoluble protein at between 1
and 1.5 mM Ca2+ (Figure 3). Mutation of one or two alter-
nate residues yielded near identical results, while mutation
of three residues resulted in a small approximately 20%
decrease in absorbance across [Ca2+]’s of 0.7 to 2 mM
(Figure 3; compare CSQ1DA3 with WT, CSQ1DA1 and
CSQ1DA2). These data indicate that these residues do
not play a major role in Ca2+-induced CSQ1 compac-
tion. CSQ1ΔC7 and CSQ1ΔC14 displayed marked differ-
ences in the Ca2+-dependent aggregation of CSQ1
(Figure 3). CSQ1ΔC7 showed some levels of Ca
2+-indu-
ced aggregation; these were much less than WT,
CSQ1DA1, CSQ1DA2, or CSQ1DA3, indicating that resi-
dues 361DDDDDDD367 are important in the formation
of the higher molecular weight entities. Remarkably,
deleting CSQ1 C-terminus severely disrupted CSQ1
ability to aggregate, presumably by disrupting Ca2+-in-
duced polymerization.
Effects of CSQ modification on in vitro interactions with
trisk95 and junctin
We tested the ability of CSQ1 to associate with trisk95
and junctin via its C-terminal residues, using co-immunoprecipitation. Purified CSQ constructs were
coupled to anti-CSQ1/agarose protein A/G, prior to
exposure to trisk95 or junctin. As has been previously
reported [42], there are significant interactions between
WT CSQ1/trisk95 and WT CSQ1/junctin at the resting
luminal [Ca2+] of 1 mM Ca2+ and ionic strength (150
mM) (Figure 4A,C first lane). A substantial interaction
between the proteins remained after mutation of one
or two alternate residues. There was a small but sig-
nificant decrease in trisk95 association with CSQ1DA3
(Figure 4A,D), indicating that 363D may play a minor
role in the trisk95-CSQ1 association. This result sug-
gests that these three alternate C-terminal residues are
not critical for the interaction with either trisk95 or
junctin.
The deletion constructs CSQ1ΔC7 and CSQ1ΔC14
reveal that the overall C-terminal tail domain heavily in-
fluences trisk95’s interaction with CSQ1. Deletion of the
entire C-terminal tail abolished CSQ1 association with
trisk95 (Figure 4A,D). Interestingly, there is a signifi-
cantly reduced band of trisk95 indicating minimal asso-
ciation with the CSQ1ΔC7 construct (Figure 4A,D),
indicating that residue 361DDDDDDD367 contributes sig-
nificantly to the trisk95-CSQ1 interaction, with a minor
contribution from 363D. The reduced CSQ1-trisk95
interaction may be due to altered Ca2+ sensitivity of the
trisk95-CSQ1 interaction, which has been shown to be
highly Ca2+-dependent [15]. There is only modest trisk95-
CSQ1 binding at resting luminal [Ca2+] (1 mM) and much
higher trisk95-CSQ1 association at lower Ca2+ concentra-
tions (approximately 100 μM) [15]. However, lowering
[Ca2+] to 100 μM did not significantly alter the degree of
Figure 4 In vitro CSQ1 binding to trisk95 and junctin. CSQ1 IP. Western blot showing binding of junctin and trisk95 to CSQ1 coupled to
anti-CSQ1/protein A/G sepharose. (A) and (C). Binding of trisk95 (A) and junctin (C) at 1 mM Ca2+ to the following CSQ constructs, from left to
right; WT CSQ1; CSQ1DA1; CSQ1DA2; CSQ1DA3; CSQ1ΔC7, and CSQ1ΔC14. (B) Binding of WT CSQ1, CSQ1ΔC7 and CSQ1ΔC14 to trisk95 at 100 μM Ca
2+.
WT CSQ1 binding to trisk95 at 1 mM Ca2+ is shown in in the first lane for comparison. Each blot in (A) to (C) was immunoprobed with antibodies
against CSQ1, trisk95, and junctin. Binding was repeated three to four times. (D) Quantitation of trisk95 and junctin association with CSQ1 C-
terminal mutants at 1 mM Ca2+. The relative percentage binding of trisk95 (gray bin) and junctin (black bin) is presented as mean ± SE. Data is
presented relative to the association of trisk95 and junctin with WT CSQ1. No band was detected for trisk95 binding to CSQ1ΔC14. Asterisks (*)
indicate average data significantly different (P ≤ 0.05) from binding of trisk95 or junctin to WT CSQ1. Molecular weight markers are to the left of
the blots in (A) and (C).
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CSQ1ΔC7 and CSQ1ΔC14 in Figure 4A (1 mM Ca
2+) with
CSQ1ΔC7 and CSQ1ΔC14 in Figure 4B (100 μM)). There-
fore, the impaired interaction is not due to a shift in Ca2+
dependence of the association but most likely due to dele-
tion of the interaction site on CSQ1 for trisk95.
In contrast to the effects on CSQ/trisk95 binding, dele-
tion of the C-terminal tail of CSQ1 severely impeded, but
did not abolish, junctin association with CSQ1 (Figure 4C,
D). Both the CSQ1ΔC7 and CSQ1ΔC14 constructs bound
approximately 50% to 80% less junctin than did WT
CSQ1 (Figure 4C; compare WT with CSQ1ΔC7 and
CSQ1ΔC14). This implies that the C-terminal tail forms a
major part of the junctin binding motif but does not con-
stitute the entire binding domain.
Effects of CSQ1 modification on the regulation of RyR1
channels by CSQ1
The functional consequence of the CSQ1 C-terminal
mutations on RyR1 regulation by CSQ1 was studied in
lipid bilayers. At a physiological resting [Ca2+] of 1 mM,
CSQ1 polymers are tethered to the RyR1 through its in-
teractions with trisk95 and junctin, allowing CSQ1 to in-
hibit native rabbit skeletal RyR1, specifically through its
association with junctin [39]. Thus, it is likely thatmutation of residues that reduce Ca2+ binding capacity
and/or inhibit interactions with junctin would alter
CSQ1’s functional effect on RyR1 gating.
Native skeletal rabbit SR vesicles (which contain the
RyR1 and its full complement of associated co-proteins)
were incorporated into lipid bilayers, and baseline activ-
ity was recorded after addition of 2 mM cis ATP and 4.5
mM trans BAPTA (to lower trans Ca2+ to 100 nM, that
is, a sub Ca2+-activated level; Figure 5A, top panel).
After approximately 3 to 5 min of stable baseline record-
ing, the Cs+ concentration in the trans chamber was
increased to 500 mM for 5 min to strip endogenous
CSQ1 from the native RyR1 [7]. The trans chamber was
then perfused with trans solution to remove dissociated
CSQ1 and to reduce trans [Cs+] to 250 mM. Dissoci-
ation of endogenous inhibitor CSQ1 from RyR1 (to yield
CSQ-dissociated RyR1) caused an increase in channel
open probability (Po), which is sustained after the re-
moval of high trans Cs+ (Figure 5A, middle trace). As
previously reported [7], re-association of WT CSQ1 with
the luminal face of the CSQ-dissociated RyR1, caused
significant inhibition of RyR1 activity, restoring channel
activity to the baseline level (Figures 5A and 6A).
Re-association of each of CSQ1DA1, CSQ1DA2, and
CSQ1DA3 with CSQ-dissociated RyR1 also inhibited
Figure 5 Deletion of the C-terminal tail, but not sequential mutation, results in ablation of CSQ1 regulation of RyR1 gating.
(A) to (D). Records of 3 s of single channel activity, where channel opening is upward from zero current (c, continuous line) to maximum open
conductance (o, broken line) at +40 mV. (A) Top trace - control activity, with 2 mM cis ATP and 100 nM cis Ca2+ free. Middle trace - channel
activity increased approximately 2 min after raising trans Cs to 500 mM, indicative of endogenous CSQ1 dissociation [33]. Bottom trace -
following perfusion of the trans chamber with control trans solution, and subsequent addition of 16 mg/ml WT CSQ1. (B) to (D) Response
of CSQ1-dissociated native RyR1 before (top) and after (bottom) addition of 16 mg/ml trans CSQ1DΔ3 (B), CSQ1ΔC7 (C), and CSQ1ΔC14 (D).
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or CSQ1DA3 caused a 2.7-fold, 2.4-fold, and 2.2-fold
decrease in channel activity, respectively (Figures 5B
and 6A,B,C,D; Table 1). The degree of inhibition by
these three constructs is reminiscent of the >2-fold de-
crease in channel activity induced by WT CSQ1
(Table 1 and [7]).
The decrease in Po in the presence of WT CSQ1 and
alanine substituted mutants CSQ1DA1-CSQ1DA3 is due to
a significant decrease in mean open time (To) (Figure 6B;
Table 1). Similar decreases in (To) were observed upon
reassociating the CSQ1 alanine mutants (Figure 6B;
Table 1). There were also significant increases in mean
closed times (Tc) of the channels, in line with those
recorded in the presence of WT CSQ1 (Figure 6C;
Table 1). As a result of the opposing changes in To and Tc,
there was no change in the overall frequency of opening
(Figure 6D).
In contrast to substitution within the final five C-
terminal residues (CSQ1DA3), deletion of the final seven
C-terminal acidic residues reduced CSQ1’s ability to
inhibit RyR1 channels (Figures 5C and 6A,B,C,D;
Table 1). While the CSQ1ΔC7 mutant inhibited channels,the inhibition was significantly less than the potent in-
hibition caused by WT CSQ1 and CSQ1DA1-CSQ1DA3.
The decrease in Po was accompanied by significant
changes in To and Tc (Figure 6B,C; Table 1). This data
correlates with the reduced ability of this construct to
induce Ca2+ compaction (Figure 3) and to bind to
junctin (Figure 4), which communicates CSQ1 signal-
ing to RyR1 [39]. Removal of the entire C-terminal tail
abolished CSQ1’s ability to inhibit the RyR1 channels
(Figures 5D and 6A,B,C,D; Table 1). Indeed, CSQ1ΔC14
evoked a small but significant activation of RyR1. This
activation is similar to the activation seen when CSQ1
is added to purified RyR1, that is, only seen when
trisk95 and junctin are absent [7,43] and indicative of
a direct, but probably non-physiological, interaction
between CSQ1 and RyR1.
To investigate the nature of the small RyR1 activation
by CSQ1ΔC14, we examined its effect on purified RyR1
(Figure 7). There was no contaminant trisk95, junctin,
or CSQ1 in this sample (Figure 7D), so that any effects
of CSQ1ΔC14 would be due to its association directly
with RyR1, rather than via the anchoring proteins. Puri-
fied RyR1 activity rose significantly approximately 1.9-
Figure 6 Ablation of CSQ1-induced RyR1 regulation is due to significant changes in channel Po, To, and Tc. Average relative data (relative
to activity before the addition of CSQ1 constructs; N = 8) showing Po, To, Tc, and Fo. (A) Relative Po (log rel Po) is the average of differences
between the log10 of Po in the presence of CSQ1 constructs (logPoCSQ) and log10 of the control Po (logPoCon; in the absence of CSQ1) for each
channel. (B) The relative mean open time (log rel To) is logToCSQ − logToCon. (C) The relative mean closed time (log rel Tc) is log TcCSQ − log TcCon.
(D) The relative mean open frequency (log rel Fo) is logFoCSQ − logFoCon. Average data significantly different (P≤ 0.05) from channel activity
recorded in the absence of WT CSQ1 is indicated by asterisk (*) and in the presence of WT CSQ1 indicated by crosshatch (#). Data were recorded
at +40 and −40 mV.
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(Figure 7A,B), although the degree of purified RyR1
activation was not as high as the approximately 2.8-
fold activation induced by WT CSQ1 (Figure 7 and
[7]). In addition, affinity chromatography shows that
both the WT CSQ1 and CSQ1ΔC14 bound to purified
RyR1 (Figure 7C). This indicates that although there
was no difference in the ability of CSQ1 to bind directly
to RyR1 in the presence or absence of the C-terminalTable 1 Comparison of changes in RyR1 channel gating param
(X ± SEM)
WT CSQ CSQ1DA1 CSQ1
RyR1-CSQ Po 0.19 ± 0.02 0.19 ± 0.03 0.17 ±
RyR1 + CSQ Po 0.08 ± 0.01* 0.07 ± 0.01* 0.06 ±
RyR1-CSQ To 4.93 ± 1.40 3.55 ± 0.26 3.44 ±
RyR1 + CSQ To 2.43 ± 0.53* 1.96 ± 0.15* 2.78 ±
RyR1-CSQ Tc 18.73 ± 4.02 25.03 ± 4.95 22.20
RyR1 + CSQ Tc 33.41 ± 4.97* 39.74 ± 10.72* 38.01
RyR1-CSQ Fo 34.15 ± 2.72 39.68 ± 3.27 41.78
RyR1 + CSQ Fo 27.32 ± 5.66 36.37 ± 8.20 39.20
Endogenous CSQ1 was first dissociated from RyR1. The first row for each parameter
CSQ1 (RyR1-CSQ1) and before addition of the recombinant CSQ1 construct. The sec
construct. Parameters are open probability (Po), open time (To), closed time (Tc), and
recorded at +40 and −40 mV. Asterisks (*) indicate average parameter significantly
(#) indicates average parameter significantly different (P ≤ 0.05) from that recordedtail, full activation of RyR1 by CSQ1 depends on bind-
ing to residues in both the C-terminal domain of CSQ1
and in the N-terminal domains. We have previously
suggested that despite CSQ1 causing a modest activation
of purified RyR1 in the bilayer, it is the overwhelming
inhibition of native RyR1 (through the CSQ1-junctin-
RyR1 interaction; [39]) which drives the overall effect of
CSQ1 in the cell, which would acts as a brake on SR Ca2+
release.eters induced by association of CSQ1 constructs
DA2 CSQ1DA3 CSQ1ΔC7 CSQ1ΔC14
0.07 0.15 ± 0.04 0.12 ± 0.01 0.12 ± 0.02
0.02* 0.07 ± 0.01* 0.10 ± 0.01*# 0.15 ± 0.01*#
0.28 3.08 ± 0.42 3.80 ± 0.48 7.09 ± 1.99
0.23* 1.99 ± 0.36* 2.67 ± 0.30* 6.70 ± 1.76#
± 6.40 33.85 ± 5.37 115.78 ± 38.29# 40.62 ± 7.81#
± 5.78* 46.14 ± 5.86#* 115.69 ± 50.11# 36.95 ± 10.40
± 5.65 32.97 ± 5.95 16.9 ± 4.50# 26.18 ± 7.95
± 7.20 27.76 ± 5.79 17.46 ± 4.40# 25.18 ± 6.49
shows average data for channel activity following dissociation of endogenous
ond row in each parameter shows average data after addition of the indicated
open frequency (Fo), which are the mean ± SE (N = 7 to 12) of combined data
different (P ≤ 0.05) from that recorded in the absence of CSQ1, and crosshatch
after addition of WT CSQ1.
AB
C D
Figure 7 CSQ1ΔC14 binds to and activates purified RyR1. (A)
Records of 3 s of single channel activity, where channel opening is
upward from zero current (c, continuous line) to maximum open
conductance (o, broken line) at +40 mV. (A) Control purified RyR1
activity, with 2 mM cis ATP and 100 nM cis Ca2+ free (top trace) and
after the addition of 16 μg/ml CSQ1ΔC14. (B) Average relative data
(relative to activity before the addition of WT CSQ1 or CSQ1ΔC14; N = 9)
showing open probability (Po). Average data significantly different (P≤
0.05) from channel activity recorded in the absence of CSQ1’s is
indicated by asterisk (*). Crosshatch (#) indicates a significant difference
(P≤ 0.05) between the average relative Po recorded in the presence of
WT CSQ1 and CSQ1ΔC14. (C) CSQ1 affinity chromotography. WT CSQ1
(left) and CSQ1ΔC14 (right) after exposure to purified RyR1. Binding was
repeated three times. Blot was immunoprobed with antibodies against
RyR1 (top) and CSQ1 (bottom). (D). Purification of RyR1 from SR
vesicles. Immunoprobing purified RyR1 sample with anti-CSQ1,
anti-trisk95, and anti-junctin shows no contaminant levels of these
proteins in the purified sample. Molecular weight marker is
between blots in (C) and (D).
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Overview
Here, we present evidence that the C-terminal tail of
CSQ1 forms the primary binding pocket for Ca2+ ions
and that it contains the CSQ1 binding sites for trisk95
and junctin and for functional interactions with RyR1.
This is also the first evaluation of the influence of
specific acidic residues on the functional characteristics
of CSQ1. Our novel data indicates the extent to which
specific acidic residues in CSQ1’s C-terminal tail influence
the Ca2+ binding capacity and Ca2+-induced aggregation
of CSQ1, its ability to bind to trisk95 and junctin and its
ability to inhibit RyR1. In summary, Ca2+ binding declines
with progressive removal of acidic residues, and all 14
acidic residues are required for the full Ca2+ binding
capacity of the wild-type protein. Deletion of one to three
of the acidic residues has little effect on Ca2+-induced
compaction or CSQ1 association with trisk95 and junctin
and does not alter the inhibitory action on RyR1 of the
CSQ1 binding to junctin. CSQ1 aggregation, binding of
trisk95 and junctin to CSQ1, and the inhibitory effect of
the binding on RyR1 activity are severely disrupted by
deletion of seven of the acidic residues and are all but
abolished by deletion of all 14 C-terminal residues.
CSQ Ca2+ binding capacity
The Ca2+ binding capacity of CSQ1 decreased when
two or more residues within the acidic C-terminal tail
were modified or deleted. CSQ1’s moderate Ca2+ bind-
ing capacity has been thought to depend on CSQ1’s
polymerization which occurs at relatively high [Ca2+]
(>0.5 mM). This model is based on the published crys-
tal structure of rabbit skeletal CSQ1 but is not sup-
ported by the crystal structure as residues 352 to 367
are not observed in the electron density mapping
(reviewed in [33]). CSQ1 dimers and polymers condense
at [Ca2+]s between 100 μM and 1 mM with a cellular ionic
strength of 150 mM [6]. The Ca2+ dependence of CSQ1’s
structure suggests that Ca2+ may act as a “glue”, interact-
ing with key acidic residues when a polymer is formed.
It is further hypothesized that residues within the
C-terminus form a Ca2+ binding sink within the struc-
tured protein which is stabilized by the formation of three
salt bridges (215E-86 K, 216E-24 K, and 169E-85 K) [27]. The
linear sequence of full-length CSQ1 cannot account for its
reported Ca2+ binding capacity, of 34 Ca2+ ions per
monomer at resting (1 mM) [Ca2+] [4]. There are insuffi-
cient acidic residues on CSQ1 to form the 34 acidic dou-
blets, assuming that one acidic double is required to bind
each Ca2+ ion [44]. The Ca2+ sink hypothesis was recently
refined, with simulation model data showing that Ca2+
preferentially saturates the C-terminal tail and induces
protein polymerization which stabilizes the formation of
many Ca2+ binding sites on CSQ1’s surface [32] which
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capacity. Our data provides the first experimental evi-
dence supporting this refined hypothesis.
Furthermore, the mutation of three acidic residues in
the C-terminal tail could only account for the loss of 3
of the 34 Ca2+ ions bound per monomer of CSQ1, yet
Ca2+ binding data illustrates an approximately 45% loss
of Ca2+ binding capacity. One interpretation of our data is
that these residues are important in stabilization of the
Ca2+ binding pocket formed upon CSQ1 polymerization
in which the ratio of Ca2+ ions to acidic doublets residues
is≫ 1. This is supported by data showing CSQ1 structure
and Ca2+ binding are drastically altered when the whole
C-terminal tail is deleted (Figure 2 and [15,29]) and the
inability of CSQ1ΔC14 to form polymers (Figure 3) under
our experimental conditions. CSQ1 is reported to be the
key luminal Ca2+ sensor for the RyR1 and to guide RyR1’s
response to the fluctuations in luminal [Ca2+] that occur
during contraction and relaxation [6,8,34]. CSQ1 binds
and releases Ca2+ in response to store load and to main-
tain free Ca2+ at approximately 1 mM and allows CSQ1 to
sense the level of Ca2+ inside the SR. Given that mutation
and deletion of the C-terminus has a profound effect on
Ca2+ binding capacity, it is likely that the C-terminal tail is
important in communicating luminal [Ca2+] to RyR1.
Loss of CSQ1 binding to trisk95 and junctin
It was not surprising that the absence of the C-terminal
tail impeded CSQ1-trisk95 association as the CSQ1
binding site for trisk95 has previously been localized to
residues within the C-terminal tail [16]. Further dissec-
tion illustrates that residues 363, 365, and 367 do not
play a pivotal role in this association, although compari-
son of binding of CSQ1DA2 and CSQ1DA3 do suggest a
minor role for 363D. It appears that residues 354 to 362
are essential in forming CSQ1’s trisk95 binding site.
It is significant that a modest amount of junctin was
able to bind to CSQ1ΔC14, given that others have
reported that the C-terminal domain of CSQ1 is the sole
binding site for junctin in skeletal muscle [15]. This is
consistent with the fact that more than one binding site
on CSQ1 may be involved in its association with junctin
in skeletal muscle, as with cardiac CSQ2 [13]. It is likely
that a binding motif, in N-terminal domains of CSQ1,
contributes to junctin association and would account the
fraction of junctin binding remaining with CSQ1ΔC7 and
CSQ1ΔC14.
Loss of CSQ1 regulatory function of RyR1 channel activity
The significant decrease in CSQ1’s ability to inhibit
RyR1 activity following deletion of 361 to 367, but that
substitution of residues 363, 365, and 367 maintain nor-
mal RyR1 regulation implies that residues 361, 362, 364,
and 366 contribute to maintaining the efficiency ofCSQ1’s regulation of RyR1 [9]. The abolition of RyR1 in-
hibition by CSQ1 when the C-terminal tail was removed
confirms both that this tail is essential in CSQ1’s role in
inhibition of Ca2+ release through RyR1 and an import-
ant role for residues 354 to 360. CSQ1 inhibition of
RyR1 activity is mediated via a RyR1/junctin/CSQ1
interaction, and not through RyR1/trisk95/CSQ1 [39].
Therefore, it is curious that CSQ1 inhibition of the
channel is lost despite the remaining modest association
of junctin with CSQ1ΔC14. It is possible that CSQ1’s
function as a channel inhibitor is directly related to its
Ca2+ binding capacity and/or structure, which is severely
reduced when the C-terminal tail is removed from
CSQ1 (Figures 2 and 3).
CSQ1 activation of RyR1 - not a physiological regulatory
mechanism?
CSQ1ΔC14 increases the activity of native RyR1 (Figure 6),
and both WT CSQ1 [7,43] and CSQ1ΔC14 activate puri-
fied RyR1 (Figure 7). It is likely that this activation is
relatively unimportant physiologically, as full-length
CSQ1 addition to RyR1 in the presence of anchors
trisk95 and junctin results in a strong channel inhibition.
In light of this, native RyR1 activation by CSQ1ΔC14 can
be explained in either of two ways. Firstly, WT CSQ1 as-
sociated with junctin exerts a dominant inhibitory effect
on RyR1 gating, so that channel inhibition overshadows
activation arising from the direct RyR1-CSQ1 associ-
ation. When the binding site on CSQ1 for junctin is
compromised in CSQ1ΔC14, channel activation by the
direct CSQ1-RyR1 coupling is unmasked. On the other
hand, the binding site for WT CSQ1 on RyR1 may be
occluded by CSQ1’s interaction with trisk95 and/or
junctin. Thus, the reduced CSQ1ΔC14 association with
trisk95 and/or junctin may expose the binding site on
RyR1 for CSQ1, allowing channel activation when
CSQ1ΔC14 is added to the trans chamber.
Conclusions
CSQ1 is unarguably the major the Ca2+ buffer inside the
SR. In addition, CSQ1 is both an inhibitor of native
RyR1 under resting conditions and also a luminal Ca2+
sensor for the channel, so that it may act as a brake on
RyR1 Ca2+ release in times of low store load [7,9]. As
mentioned above, CSQ1 has been thought to regulate
RyR1 via interactions with trisk95 and junctin. Our pre-
vious single channel data suggests that junctin, but not
trisk95, is the key intermediate protein in RyR1 inhib-
ition [39], although evidence from one trisk95 and
junctin knockout study suggests that trisk95 is the pref-
erential anchor for CSQ1 [45]. On the other hand,
studies using myotubes deficient of trisk95 and junctin
confirm our observations that junctin’s primary role is
in communication of luminal Ca2+ to RyR1 [46]. It
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tion are in fact separate processes. Regardless, CSQ1
undisputedly plays an important role in regulating RyR1
and in excitation-contraction coupling. The essential na-
ture of CSQ1 is illustrated in CSQ1-null mice, which ex-
hibit increased susceptibility to stress in a similar manner
to exertional/environmental heat stroke and to human
malignant hyperthermia (MH) a life-threatening hyper-
metabolic disorder induced by treatment with volatile
anesthetics and the muscle relaxant succinylcholine
[10,47,48]. This complex phenotype is likely initiated by
abnormal Ca2+ handling by the SR, due to lack of CSQ1
inhibition on RyR1 activity [47].
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